Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

The FDA has granted Orphan Drug designation to riliprubart for the investigational treatment of AMR in solid organ transplantation.

In Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart for the investigational treatment of antibody-mediated rejection ...

Frontiers Events is a rapidly growing calendar management system dedicated to the scheduling of academic events. This includes announcements and invitations, participant listings and search ...

Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU ...

The researchers concluded that the higher levels of C1s and C1-inhibitor in the serum and plasma of patients with MG suggest the early activation of the classical complement pathway. “These findings ...

Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative ...

A growing body of evidence suggests that complement dysregulation plays a role in the pathogenesis of preeclampsia. The kidney is one of the major organs affected in preeclampsia. Because the kidney ...

ImmunAbs believes that comprehensive inhibition of both the classical and alternative pathways is essential for minimizing ... IM-101 is a humanized monoclonal antibody targeting complement C5 ...